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procedures done at our institution over an 18 month period. Radiation
exposure was categorized per procedures. Estimated Skin Dose (ESD)
(mGy) and Effective Dose (mSv) were calculated. Also, total CT scans were
tabulated for patients undergoing aneurysm stent grafting and cumulative
ED was estimated. Statistical analyses were done with Kruskal-Wallis tests to
detect overall differences, Wilcoxon Rank Sum Exact tests for paired com-
parisons, and for group comparisons a Bonferroni post hoc test.
Results: 2103 interventions in 1111 patients had fluoroscopy times
recorded during this period. As expected, the more complex the procedure,
the longer the fluoroscopy time and ESD, with patients undergoing atherec-
tomy (ATH) having significantly higher ESD than all groups (1260
(900,1542); p.001) (mGy) which was approaching the skin injury thresh-
old of 2000 (mGy). When measuring ED, Cerebrovascular intervention
(CVI) and infrarenal aortic aneurysm (IAA) received the highest ED (120
(100,150), 109(85,151); p.001) (mSv) among other groups. When com-
paring different aneurysm repairs, TAA patients underwent a greater number
of CT scans than IAA (7.40.3 vs 5.80.2; P0.004). After tabulating the
cumulative ED including procedure and CT scans, IAA patients had signif-
icantly higher doses of radiation exposure than TAA ( 2175, 1916 .;
P0.004).
Conclusions: With increasing complexity of endovascular interven-
tions, there is increased radiation exposure to all involved with highest doses
coming from those undergoing any aneurysm repair. Future innovations
should concentrate on reducing the risk of radiation exposure to all person-
nel and newer imaging modalities.
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Objectives: Technological advances in Vascular Surgery have pro-
duced a complex relationship between pharmaceutical corporations and
surgeons. However, the influence of industry on scientific presentations at
national meetings is not known. This study describes the prevalence and
patterns of reported Conflict of Interest (COI) at the Society of Vascular
Surgery (SVS) annual conference.
Methods: Data from the programs of the annual SVS meetings from
2005 (when COI disclosure was first required) to 2008 were analyzed.
Results: The percentage of authors declaring at least one COI has
changed little: in 2005, 23% of authors declared at least one COI, compared
to 26% in 2008. However, the number of authors disclosing multiple COI
has increased. Of authors disclosing any COI in 2005, nearly half disclosed
only one; in 2008, more than two thirds disclosed multiple (Graph). Of all
scientific papers presented in 2008 at SVS, 21% had at least one author
declaring COI; of note, at the PVSS session featuring young vascular
surgeons, the incidence was nearly double, 41%.
Conclusions: The influence of industry on the SVS conference has
increased in the past four years. The frequency of COI disclosures at the
PVSS session underscores the importance of endovascular innovation in
which young vascular surgeons may be more likely to be involved. It may
also reflect an evolving emphasis on the “business” of medicine, a concept to
which recently trained surgeons have greater exposure. These results support
the establishment of a comprehensive COI management plan to ensure that
the scientific integrity of the SVS is not undermined by COI. Further study
is needed to determine whether surgeons’ relationships with industry affect
surgical decision making or patient care.Author Disclosures: E. Grossman, None; P. Angelos, Ethicon Endosur-
gery; T. Desai, None.
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Objective: To assess rates of medication compliance in vascular pa-
tients.
Methods: A prospective study of consecutive patients seen in Vascular
Clinic at a busy tertiary academic center. Patients were interviewed via
standardized questionnaire and evaluated co-existing medical conditions
and medication use. Optimal medical therapy was defined as the 2006
AHA/ACC Guidelines for Secondary Prevention for Atherosclerotic Vas-
cular Disease.
Results: 180 patients were seen in various vascular surgery clinics
affiliated in a 4 month period. Co-morbid conditions surveyed included
HTN (n134), DM (n50), CAD (n19), hypercholesterolemia (n84),
and ESRD (n8). 54% of the patients were male. 58% of the patients were
insured, 34% were uninsured. 18% were current smokers, 68% were non-
smokers. We found that 43% of all patients were receiving inadequate
medical therapy for their co-morbid conditions. Uninsured patients were
more likely (56%) than insured patients (34%) to receive inadequate thera-
py.Lack of insurance was a predictor of inadequate treatment of HTN
(OR3.05, C.I. 1.12-8.3, p0.025), hypercholesterolemia (OR4.5, C.I.
1.4-14.3, p0.007), and any disease overall (OR2.4, C.I. 1.2-4.7,
p0.01) (Fig). Overall, males (49%) were more likely than females (36%) to
receive inadequate medical therapy, especially relating to PVD (OR5.25,
C.I. 1.6-17.3, p0.004). The incidence of suboptimal management was
37% for zero to two co-morbid conditions, but increased to 100% for five
co-morbid conditions.
Conclusions: Uninsured patients were more likely to receive inade-
quate medical therapy than their insured counterparts. This survey provides
sobering statistics regarding medical compliance in a real world medical
practice.
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Background: Tumor invasion or adherence of the pancreas to the
portal vein (PV) complicates pancreaticoduondenectomy. Lower extremity
vein (LEV) can provide autogenous conduits for PV reconstruction in such
cases. Little data exist, however, describing PV reconstruction techniques,
morbidity or patency using LE vein as part of pancreaticoduondenectomy.
Methods: We analyzed preoperative imaging, reconstructive tech-
niques, perioperative morbidity related to LEV vein harvest, and reconstruc-
tion patency in patients undergoing PV reconstruction during pancreati-
coduondenectomy.
Results: Thirty-one of 227 patients (14%) undergoing pancreati-
coduondenectomy had PV reconstruction using LEV. Mean age was 63
years. Preoperative imaging indicated tumor adherence or invasion of the
PV in only 39% of the patients requiring PV reconstruction. Preoperative
vein mapping influenced the choice of LEV used for reconstruction by
identifying abnormalities in 47%. Reconstruction technique (patch vs.
replacement) was determined by extent of PV adherence / invasion. PV
patching using greater saphenous vein (GSV) or femoral vein (FV) was
performed in 19 cases (61%) and PV replacement using FV was required
in 12 cases (39%). Wound complications or ipsilateral DVT occurred in
no patients with GSV harvests and in 38% of patients with FV harvests, p
0.019. Two reoperations were required for wound complications.
There was one intraoperative PV thrombosis requiring revision, one
occlusion in 30 days and 1 known late occlusion secondary to local
disease recurrence. Twelve month patency of PV reconstruction was 96%
with a mean follow-up of 5.4 months.
Conclusions: Preoperative imaging may fail to confirm PV involve-
ment in patients undergoing pancreaticoduodenectomy. Preoperative vein
mapping influences conduit choice in patients requiring PV reconstruction
and should be performed prior to pancreaticoduodenectomy. Minimal
morbidity is associated with GSV harvest while FV harvest is associated with
manageable complications. PV reconstruction with LEV provides excellent
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during pancreaticoduodenectomy.
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Background: Chronic atrial fibrillation (AF) is associated with a poor
outcome due to cardiovascular events. The outcome of new-onset AF
during vascular surgery is unknown. New-onset AFmight be induced by the
stress of surgery or as a consequence of myocardial ischemia. Continuous
electrocardiography (cont-ECG) can assess myocardial ischemia by ST-
segment analysis, new-onset AF and their relation in time.
Aim: To study the prognosis of new-onset AF in vascular surgery
patients.
Methods: 351 patients, all in sinus rhythm, scheduled for vascular
surgery were screened for cardiac risk factors and left ventricular function
(NT-proBNP). Cont-ECG for 72 hours was used to identify new-onset AF
and ischemia. Events were the composite of death, stroke, andMI, scored at
30-days after surgery and during late follow-up. A MI was defined by
troponin release and ECG changes. Mean follow-up was 1.6 years.
Results: New-onset AF developed in 17(5%) patients and myocardial
ischemia in 72(20%) patients. The composite endpoint after 30-days and
during late follow-up occurred in 15(4.2%) and 35(10%) patients respec-
tively. Multivariate regression analysis showed that new-onset AF was asso-
ciated with the 30-day endpoint (OR 4.2 95% CI 1.2-15) and the late
endpoint (HR 3.5 95% CI 1.5-8.5, figure). New-onset AF was preceded by
ischemia in 8/17 patients on average by 484 minutes (range 60-3204 min).NT-proBNP was significantly higher in patients with new-onset AF; 943 vs
218 pg/ml respectively (p0.01).
Conclusion: New-onset AF during vascular surgery is associated with
an increased incidence of 30-day and late cardiocerebrovascular events. Half
of the new-onset AF occurs in non-ischemic patients and is associated with a
reduced left ventricular function.
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